EpiVax Appoints Dr. Vibha Jawa as New Chief Scientific Officer to Lead Scientific Strategy
EpiVax, Inc., a prominent name in preclinical immunogenicity assessment for biologics and vaccines, has made a significant leadership change by appointing Dr. Vibha Jawa, PhD, FAAPS, as its new Chief Scientific Officer (CSO). This move is part of a strategic overhaul as Dr. Jawa takes over from the company's founder and current Chief Medical Officer, Dr. Annie De Groot, who previously held the CSO position.
Dr. Jawa brings with her a wealth of experience, having worked for over twenty years in the development of biologics, vaccines, and gene therapies. She most recently served as the Executive Director of Translational Medicine at Bristol Myers Squibb, where she spearheaded bioanalytical strategy and supported preclinical and clinical evaluations related to pharmacokinetics (PK) and immunogenicity throughout various development pipelines. Her leadership roles at prominent companies like Merck and Amgen have equipped her to guide projects that range from discovery to full development. Notably, she has actively contributed to a number of successful Investigational New Drug (IND), Biologics License Application (BLA), and Marketing Authorization Application (MAA) submissions across various therapeutic modalities, including participation in the team at the Institute of Human Gene Therapy at UPENN that supported the first approved gene therapy product.
A distinguished thought leader in bioanalysis and immunogenicity strategy, Dr. Jawa has authored over 100 peer-reviewed publications, showcasing her expertise in the field. Her recognition extends to significant roles in various reputable scientific organizations and consortia, such as the American Association of Pharmaceutical Scientists (AAPS) and the Immunology Quality (IQ) consortium. In 2022, she was elected as a member of AAPS in recognition of her impactful contributions.
"We are thrilled to have Vibha join our team," remarked Dr. Rich-Henry Schabowsky, CEO of EpiVax. "Her extensive experience with biologics, especially with novel modalities, combined with her expertise in assessing and mitigating immunogenic risks, will enhance our methodologies to meet the complex demands of the industry."
Dr. Annie De Groot added, "Vibha is the ideal scientific leader for EpiVax 2.0. She embodies the energy that EpiVax needs during this transition period. I am excited to pass the torch to Dr. Jawa, who will ensure that EpiVax remains at the forefront of immunogenicity research—pushing boundaries, validating new ideas, bridging in vitro data with immunoinformatics and AI, and setting higher standards in translational immunology."
In the dual role of CSO, Dr. Jawa will be responsible for both external and internal scientific endeavors. She will represent EpiVax at significant conferences while simultaneously overseeing internal research and validation efforts. Her leadership is anticipated to broaden the company's reach into new therapeutic areas and fortify EpiVax's reputation as a reliable partner in the development of biologics and vaccines.
"Joining the EpiVax team excites me immensely," said Dr. Jawa. "This is an exceptional organization known for its scientific leadership in immunogenicity assessment. I look forward to building upon this legacy and further refining the team's approaches to provide the most accurate and insightful support."
EpiVax is a leader in preclinical immunogenicity assessment and sequence optimization for peptide therapeutics, biologics, gene/cell therapies, and vaccines. The company collaborates with numerous global firms, agencies, and researchers to expedite the evaluation of immunogenicity risks, immunomodulation, and the accelerated development of vaccines.
Dr. Jawa brings with her a wealth of experience, having worked for over twenty years in the development of biologics, vaccines, and gene therapies. She most recently served as the Executive Director of Translational Medicine at Bristol Myers Squibb, where she spearheaded bioanalytical strategy and supported preclinical and clinical evaluations related to pharmacokinetics (PK) and immunogenicity throughout various development pipelines. Her leadership roles at prominent companies like Merck and Amgen have equipped her to guide projects that range from discovery to full development. Notably, she has actively contributed to a number of successful Investigational New Drug (IND), Biologics License Application (BLA), and Marketing Authorization Application (MAA) submissions across various therapeutic modalities, including participation in the team at the Institute of Human Gene Therapy at UPENN that supported the first approved gene therapy product.
A distinguished thought leader in bioanalysis and immunogenicity strategy, Dr. Jawa has authored over 100 peer-reviewed publications, showcasing her expertise in the field. Her recognition extends to significant roles in various reputable scientific organizations and consortia, such as the American Association of Pharmaceutical Scientists (AAPS) and the Immunology Quality (IQ) consortium. In 2022, she was elected as a member of AAPS in recognition of her impactful contributions.
"We are thrilled to have Vibha join our team," remarked Dr. Rich-Henry Schabowsky, CEO of EpiVax. "Her extensive experience with biologics, especially with novel modalities, combined with her expertise in assessing and mitigating immunogenic risks, will enhance our methodologies to meet the complex demands of the industry."
Dr. Annie De Groot added, "Vibha is the ideal scientific leader for EpiVax 2.0. She embodies the energy that EpiVax needs during this transition period. I am excited to pass the torch to Dr. Jawa, who will ensure that EpiVax remains at the forefront of immunogenicity research—pushing boundaries, validating new ideas, bridging in vitro data with immunoinformatics and AI, and setting higher standards in translational immunology."
In the dual role of CSO, Dr. Jawa will be responsible for both external and internal scientific endeavors. She will represent EpiVax at significant conferences while simultaneously overseeing internal research and validation efforts. Her leadership is anticipated to broaden the company's reach into new therapeutic areas and fortify EpiVax's reputation as a reliable partner in the development of biologics and vaccines.
"Joining the EpiVax team excites me immensely," said Dr. Jawa. "This is an exceptional organization known for its scientific leadership in immunogenicity assessment. I look forward to building upon this legacy and further refining the team's approaches to provide the most accurate and insightful support."
EpiVax is a leader in preclinical immunogenicity assessment and sequence optimization for peptide therapeutics, biologics, gene/cell therapies, and vaccines. The company collaborates with numerous global firms, agencies, and researchers to expedite the evaluation of immunogenicity risks, immunomodulation, and the accelerated development of vaccines.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.